Systematix continues to expect HCLTech to deliver above-industry growth in FY27E and FY28E, underpinned by strong bookings, improving traction in large accounts, continued investment and its longterm AI ambitions, these include building full-stack AI services and taking a minority stake in Sarvam AI.
Systematix continues to expect HCLTech to deliver above-industry growth in FY27E and FY28E, underpinned by strong bookings, improving traction in large accounts, continued investment and its longterm AI ambitions, these include building full-stack AI services and taking a minority stake in Sarvam AI.
<iframe src="https://hindustansphere.com/embed/cluster/69b3e19af0e2332404bf300c721adc20587fc930" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="HCLTech Q2 Review: Systematix Revises Target Price After Margin, Profit Beat; Details Inside"></iframe>
